Deal-Making Accelerates As Innovation Challenges Proliferate
This article was originally published in The Gray Sheet
Executive Summary
Merger and acquisition activity is experiencing a rebound in 2010 following a steep plunge in 2009, but burgeoning challenges to innovation will require changes for medical technology firms to succeed, according to an Ernst & Young report.
You may also be interested in...
NEWS IN BRIEF
FDA closes underused pilot Multipurpose Audit Program
Opportunities Ripe For Device Firms In Emerging-Market Heartlands
Device and diagnostics companies can find new growth opportunities by marketing their wares in developing countries' smaller cities and towns, not just big ones, experts said Sept. 30 at a Wells Fargo Securities Emerging Markets Forum in New York
Novartis Completes Deal For Nestle's Share In Alcon
For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008